Swiss National Bank bought a new position in shares of Kodiak Sciences Inc. (NASDAQ:KOD – Free Report) in the first quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor bought 57,400 shares of the company’s stock, valued at approximately $2,188,000.
Several other large investors also recently modified their holdings of KOD. Westfuller Advisors LLC bought a new position in Kodiak Sciences during the 1st quarter valued at approximately $26,000. V Square Quantitative Management LLC bought a new position in shares of Kodiak Sciences during the first quarter valued at approximately $26,000. EverSource Wealth Advisors LLC lifted its stake in Kodiak Sciences by 1,221.3% in the fourth quarter. EverSource Wealth Advisors LLC now owns 991 shares of the company’s stock worth $28,000 after acquiring an additional 916 shares during the period. GF Fund Management CO. LTD. bought a new stake in Kodiak Sciences in the fourth quarter valued at $29,000. Finally, Headlands Technologies LLC increased its position in Kodiak Sciences by 256.4% during the 2nd quarter. Headlands Technologies LLC now owns 8,083 shares of the company’s stock valued at $30,000 after purchasing an additional 5,815 shares during the period. 89.06% of the stock is owned by institutional investors.
Kodiak Sciences Price Performance
Shares of NASDAQ KOD opened at $42.50 on Friday. Kodiak Sciences Inc. has a 1 year low of $6.21 and a 1 year high of $47.84. The firm has a 50-day moving average of $37.44 and a 200 day moving average of $33.81. The stock has a market cap of $2.66 billion, a P/E ratio of -10.19 and a beta of 2.19.
Analysts Set New Price Targets
Several equities research analysts have recently commented on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Kodiak Sciences in a research report on Friday, July 10th. Chardan Capital upgraded shares of Kodiak Sciences from a “neutral” rating to a “buy” rating and boosted their price target for the company from $14.00 to $61.00 in a research report on Monday, May 11th. Finally, Wall Street Zen upgraded shares of Kodiak Sciences from a “sell” rating to a “hold” rating in a report on Saturday, May 16th. Six analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $42.14.
Get Our Latest Analysis on Kodiak Sciences
Kodiak Sciences Profile
Kodiak Sciences, Inc is a clinical‐stage biopharmaceutical company headquartered in Palo Alto, California, that focuses on the discovery and development of novel therapies for retinal diseases. The company’s proprietary technology centers on antibody biopolymer conjugates (ABCs), which are designed to extend durability, enhance tissue penetration and improve the safety profile of existing therapeutic modalities. Kodiak’s research and development efforts target conditions such as wet age-related macular degeneration (wet AMD), diabetic macular edema (DME) and other serious ophthalmic disorders.
The lead product candidate in Kodiak’s pipeline is KSI-301, an anti-VEGF antibody biopolymer conjugate administered via intravitreal injection.
Read More
- Five stocks we like better than Kodiak Sciences
- Microsoft Just Flipped the AI Spending Narrative Overnight
- Qualcomm’s Turnaround Is Working, So Why Is Wall Street Selling?
- Meta’s Earnings Show Why Wall Street Is Losing Patience With AI Spending
- Can Starbucks Keep This Turnaround Going? The Latest Results Say Yes
Want to see what other hedge funds are holding KOD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Kodiak Sciences Inc. (NASDAQ:KOD – Free Report).
Receive News & Ratings for Kodiak Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kodiak Sciences and related companies with MarketBeat.com's FREE daily email newsletter.
